Allena Pharmaceuticals, Inc. Current Part of Debt

Current Part of Debt of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending December 31, 2021 was $10.2 Million (a 3289.67% increase compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt increased by 3935.32%
  • Annual Current Part of Debt for 2021 was $10.2 Million (a 3394.5% increase from previous year)
  • Annual Current Part of Debt for 2020 was $291 Thousand (a -93.52% decrease from previous year)
  • Annual Current Part of Debt for 2019 was $4.49 Million (a 16.02% increase from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Allena Pharmaceuticals, Inc.

Most recent Current Part of Debtof ALNA including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $10.17 $0.3 $0.3 $0.25 $10.17
2020 $0.29 $0.17 $4.29 $4.42 $0.29
2019 $4.49 $0.53 $0.52 $0.51 $4.49
2017 $3.87
2016 $0.18

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.